Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATA 188

Next Previous
Search
Drug Profile

ATA 188

Alternative Names: Allogeneic ATA 188; Allogeneic EBV-directed T-cell therapy; ATA-188; EBV-CTLs; EBV-targeted T-cell; Epstein-Barr Virus-directed cytotoxic T lymphocytes; Off-the-shelf ATA188

Latest Information Update: 05 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Atara Biotherapeutics
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 04 Apr 2024 ATA 188 is available for licensing as of 05 Apr 2024. https://www.sec.gov/ix?doc=/Archives/edgar/data/1604464/000095017024037644/atra-20231231.htm
  • 04 Apr 2024 Atara Biotherapeutics paused the development for Multiple sclerosis (Atara Biotherapeutics SEC 2024)
  • 17 Jan 2024 Atara Biotherapeutics terminates a phase I/II EMBOLD trial in Multiple sclerosis (Treatment-experienced) in USA, Australia, and Canada (IV), due to the primary endpoint not being achieved (NCT03283826)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top